1. Record Nr. UNISA996388977803316

Autore	J. P
Titolo	Proposals humbly offered to the consideration of the Parliament, to repair the loss by three millions of clipp'd money [[electronic resource]] : without any charge to the nation for fifteen years, viz
Pubbl/distr/stampa	[London?, : s.n., 1695]
Descrizione fisica	1 sheet ([1] p.)
Soggetti	Finance - Great Britain Great Britain History 1689-1714 Early works to 1800
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Imprint from Wing. Signed at end: J.P. T.B. Reproduction of the original in the Baker Library, Graduate School of Business Administration, Harvard University Library.
Sommario/riassunto	eebo-0062

2. Record Nr. UNINA9910895780703321

Titolo	Archives of computational materials science and surface engineering
Pubbl/distr/stampa	Gliwice, : Association of Computational Materials Science and Surface Engineering
Descrizione fisica	1 online resource
Soggetti	Surfaces (Technology) Materials - Computer simulation Materials - Mathematical models Periodicals.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Periodico

3. Record Nr. UNINA9910350320203321

Titolo	Drug Discovery in Japan : Investigating the Sources of Innovation / / edited by Sadao Nagaoka
Pubbl/distr/stampa	Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019
ISBN	981-13-8906-3
Edizione	[1st ed. 2019.]
Descrizione fisica	1 online resource (xv, 333 pages) : illustrations
Disciplina	615.190941
Soggetti	Economic policy Management Industrial management Japan—History R & D/Technology Policy Innovation/Technology Management History of Japan
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.

Nota di contenuto	Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
Sommario/riassunto	This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.